Literature DB >> 34038697

Molecular Signatures of Idiopathic Pulmonary Fibrosis.

Iain R Konigsberg1, Raphael Borie2, Avram D Walts1, Jonathan Cardwell1, Mauricio Rojas3, Fabian Metzger4, Stefanie M Hauck4, Tasha E Fingerlin5, Ivana V Yang1, David A Schwartz1.   

Abstract

Molecular patterns and pathways in idiopathic pulmonary fibrosis (IPF) have been extensively investigated, but few studies have assimilated multiomic platforms to provide an integrative understanding of molecular patterns that are relevant in IPF. Herein, we combine the coding and noncoding transcriptomes, DNA methylomes, and proteomes from IPF and healthy lung tissue to identify molecules and pathways associated with this disease. RNA sequencing, Illumina MethylationEPIC array, and liquid chromatography-mass spectrometry proteomic data were collected on lung tissue from 24 subjects with IPF and 14 control subjects. Significant differential features were identified by using linear models adjusting for age and sex, inflation, and bias when appropriate. Data Integration Analysis for Biomarker Discovery Using a Latent Component Method for Omics Studies was used for integrative multiomic analysis. We identified 4,643 differentially expressed transcripts aligning to 3,439 genes, 998 differentially abundant proteins, 2,500 differentially methylated regions, and 1,269 differentially expressed long noncoding RNAs (lncRNAs) that were significant after correcting for multiple tests (false discovery rate < 0.05). Unsupervised hierarchical clustering using 20 coding mRNA, protein, methylation, and lncRNA features with the highest loadings on the top latent variable from the four data sets demonstrates perfect separation of IPF and control lungs. Our analysis confirmed previously validated molecules and pathways known to be dysregulated in disease and implicated novel molecular features as potential drivers and modifiers of disease. For example, 4 proteins, 18 differentially methylated regions, and 10 lncRNAs were found to have strong correlations (|r| > 0.8) with MMP7 (matrix metalloproteinase 7). Therefore, by using a system biology approach, we have identified novel molecular relationships in IPF.

Entities:  

Keywords:  methylome; multiomics; proteome; systems biology; transcriptome

Mesh:

Substances:

Year:  2021        PMID: 34038697      PMCID: PMC8525208          DOI: 10.1165/rcmb.2020-0546OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   7.748


  71 in total

Review 1.  Microarray analysis of idiopathic pulmonary fibrosis.

Authors:  Naftali Kaminski
Journal:  Am J Respir Cell Mol Biol       Date:  2003-09       Impact factor: 6.914

2.  The sva package for removing batch effects and other unwanted variation in high-throughput experiments.

Authors:  Jeffrey T Leek; W Evan Johnson; Hilary S Parker; Andrew E Jaffe; John D Storey
Journal:  Bioinformatics       Date:  2012-01-17       Impact factor: 6.937

3.  Altered DNA methylation profile in idiopathic pulmonary fibrosis.

Authors:  Yan Y Sanders; Namasivayam Ambalavanan; Brian Halloran; Xiangyu Zhang; Hui Liu; David K Crossman; Molly Bray; Kui Zhang; Victor J Thannickal; James S Hagood
Journal:  Am J Respir Crit Care Med       Date:  2012-06-14       Impact factor: 21.405

4.  MUC5B Promoter Variant rs35705950 Affects MUC5B Expression in the Distal Airways in Idiopathic Pulmonary Fibrosis.

Authors:  Yasushi Nakano; Ivana V Yang; Avram D Walts; Alan M Watson; Britney A Helling; Ashley A Fletcher; Abigail R Lara; Marvin I Schwarz; Christopher M Evans; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2016-02-15       Impact factor: 21.405

5.  Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.

Authors:  Yan Y Sanders; Annie Pardo; Moisés Selman; Gerard J Nuovo; Trygve O Tollefsbol; Gene P Siegal; James S Hagood
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-12       Impact factor: 6.914

6.  Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans.

Authors:  Fengrong Zuo; Naftali Kaminski; Elsie Eugui; John Allard; Zohar Yakhini; Amir Ben-Dor; Lance Lollini; David Morris; Yong Kim; Barbara DeLustro; Dean Sheppard; Annie Pardo; Moises Selman; Renu A Heller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

7.  Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10.

Authors:  Andrew M Tager; Richard L Kradin; Peter LaCamera; Scott D Bercury; Gabriele S V Campanella; Carol P Leary; Vasiliy Polosukhin; Long-Hai Zhao; Hideo Sakamoto; Timothy S Blackwell; Andrew D Luster
Journal:  Am J Respir Cell Mol Biol       Date:  2004-06-17       Impact factor: 6.914

8.  Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).

Authors:  Kathy Boon; Nathaniel W Bailey; Jun Yang; Mark P Steel; Steve Groshong; Dolly Kervitsky; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

9.  Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer.

Authors:  Youyou Zhang; Qun He; Zhongyi Hu; Yi Feng; Lingling Fan; Zhaoqing Tang; Jiao Yuan; Weiwei Shan; Chunsheng Li; Xiaowen Hu; Janos L Tanyi; Yi Fan; Qihong Huang; Kathleen Montone; Chi V Dang; Lin Zhang
Journal:  Nat Struct Mol Biol       Date:  2016-04-25       Impact factor: 15.369

10.  Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis.

Authors:  Arun C Habermann; Austin J Gutierrez; Linh T Bui; Stephanie L Yahn; Nichelle I Winters; Carla L Calvi; Lance Peter; Mei-I Chung; Chase J Taylor; Christopher Jetter; Latha Raju; Jamie Roberson; Guixiao Ding; Lori Wood; Jennifer M S Sucre; Bradley W Richmond; Ana P Serezani; Wyatt J McDonnell; Simon B Mallal; Matthew J Bacchetta; James E Loyd; Ciara M Shaver; Lorraine B Ware; Ross Bremner; Rajat Walia; Timothy S Blackwell; Nicholas E Banovich; Jonathan A Kropski
Journal:  Sci Adv       Date:  2020-07-08       Impact factor: 14.136

View more
  6 in total

1.  Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.

Authors:  Peiyan Zheng; Shixue Sun; Jingxian Wang; Xiaohua Douglas Zhang; Baoqing Sun; Zhangkai Jason Cheng; Kuan Cheok Lei; Mingshan Xue; Teng Zhang; Huimin Huang
Journal:  Cell Mol Life Sci       Date:  2022-01-11       Impact factor: 9.261

Review 2.  Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.

Authors:  Alesandra Florescu; Florin Liviu Gherghina; Anca Emanuela Mușetescu; Vlad Pădureanu; Anca Roșu; Mirela Marinela Florescu; Cristina Criveanu; Lucian-Mihai Florescu; Anca Bobircă
Journal:  Biomedicines       Date:  2022-06-09

Review 3.  Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play.

Authors:  Lourdes Chuliá-Peris; Cristina Carreres-Rey; Marta Gabasa; Jordi Alcaraz; Julián Carretero; Javier Pereda
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

4.  Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis.

Authors:  Pitchumani Sivakumar; Ron Ammar; John Ryan Thompson; Yi Luo; Denis Streltsov; Mary Porteous; Carly McCoubrey; Edward Cantu; Michael F Beers; Gabor Jarai; Jason D Christie
Journal:  Respir Res       Date:  2021-10-24

Review 5.  Idiopathic pulmonary fibrosis: Current and future treatment.

Authors:  Daniel S Glass; David Grossfeld; Heather A Renna; Priya Agarwala; Peter Spiegler; Joshua DeLeon; Allison B Reiss
Journal:  Clin Respir J       Date:  2022-01-10       Impact factor: 1.761

Review 6.  Contemporary Concise Review 2021: Interstitial lung disease.

Authors:  Cormac McCarthy; Michael P Keane
Journal:  Respirology       Date:  2022-05-05       Impact factor: 6.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.